Anocca understands the complexity of T-cell biology. We have established a unique technology platform that replicates functional human cellular immunobiology and unlocks the potential of T-cell immunotherapies and vaccine strategies that leverage T-cell immunity.
Anocca’s approach and proprietary technologies deliver the means to efficiently and precisely harness and manipulate T-cell immunity, enabling a range of next-generation therapies and vaccination strategies that address unmet patient need in oncology, infectious disease and autoimmunity.
Today Anocca has a focus on delivering T-cell receptor-modified T-cell therapies (TCR-T) in oncology. Anocca is rapidly progressing a pipeline of novel therapeutic TCR-T candidates generated entirely with our own technologies towards clinical trials utilising our in-house state-of-the-art manufacturing capabilities and processes.
Anocca’s approach and proprietary technologies deliver the means to efficiently and precisely harness and manipulate T-cell immunity, enabling a range of next-generation therapies and vaccination strategies that address unmet patient need in oncology, infectious disease and autoimmunity.
Today Anocca has a focus on delivering T-cell receptor-modified T-cell therapies (TCR-T) in oncology. Anocca is rapidly progressing a pipeline of novel therapeutic TCR-T candidates generated entirely with our own technologies towards clinical trials utilising our in-house state-of-the-art manufacturing capabilities and processes.
Location: Sweden, Södertälje
Employees: 51-200
Total raised: $110.8M
Founded date: 2014
Funding Rounds 3
| Date | Series | Amount | Investors |
| 31.05.2023 | - | $36.69M | - |
| 22.12.2022 | - | $26.55M | - |
| 22.07.2021 | Series B | $47.56M | - |
Mentions in press and media 10
| Date | Title | Description |
| 26.11.2024 | Anocca Announces Submission of Clinical Trial Application for Multi-asset Trial VIDAR-1 in Advanced Pancreatic Cancer | Anocca Announces Submission of Clinical Trial Application for Multi-asset Trial VIDAR-1 in Advanced Pancreatic Cancer Tue, Nov 26, 2024 09:00 CET Report this content Application to the European Medicines Agency (EMA) covers ANOC-001 as the ... |
| 30.05.2024 | Anocca AB and Shinobi Therapeutics Announce Strategic Partnership to Develop Allogeneic TCR-T Cell Therapies in Oncology | Anocca AB and Shinobi Therapeutics Announce Strategic Partnership to Develop Allogeneic TCR-T Cell Therapies in Oncology Thu, May 30, 2024 12:00 CET Report this content Södertälje, Sweden, & San Francisco, USA and Kyoto, Japan, 30 May 2... |
| 31.05.2023 | Anocca Raises USD36.58M in Equity Funding | Anocca AB, a Södertälje, Sweden-based developer of cancer cell therapies, raised SEK 400m (approx. USD36.58M) in equity financing. The round was led by AMF and Mellby Gård, with participation from Michano, Swedbank Robur, Ramsbury, Nidoco a... |
| 31.05.2023 | Anocca raises SEK 400 million for large-scale development of cancer cell therapies | - |
| 22.12.2022 | Sweden-based Anocca secures €25M from EIB to develop T-cell therapies for cancer | Södertälje-based Anocca, a fully integrated cell therapy biotechnology company, announced on Wednesday, December 21, that it has raised €25M in venture debt funding from the European Investment Bank (EIB). Paolo Gentiloni, European Commissi... |
| 21.12.2022 | Anocca Secures EUR 25M from the European Investment Bank | Anocca, a Södertälje, Sweden-based cell therapy biotechnology company, received €25M in Venture Debt. The European Investment Bank made the financing. The company intends to use the funds to move T-cell immunotherapies towards clinical tria... |
| 02.08.2021 | Sweden’s Anocca raises €40M to develop novel therapeutics for cancer, infectious disease, autoimmunity | T-Cells are crucial immune cells capable of recognising cancers over healthy cells. Utilising the immune system to recognise and destroy tumour cells has been the primary goal of anti-cancer immunotherapy. Recently, there has been an increa... |
| 22.07.2021 | Anocca : Raises $47m in a Series B Financing to Advance Its Industrialised Approach to TCR-T Cellular Immunotherapy | Anocca AB, a leader in unlocking the potential of T-cell immunotherapy to deliver transformative therapeutics for cancer, today announced the closing of a USD 47 million (SEK 400 million) Series B financing to further advance the company’s ... |
| 22.07.2021 | Anocca Raises $47M in Series B Financing | Anocca AB, a Sodertalje, Sweden-based developer of therapeutics for cancer leveraging the potential of T-cell immunotherapy, closed a USD 47m (SEK 400m) Series B financing. Backers included Swedbank Robur Ny Teknik, Ramsbury Invest and fami... |
| - | Anocca AB | “Anocca | A Swedish privately funded biotech company” |